期刊
ANTICANCER RESEARCH
卷 37, 期 2, 页码 853-858出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.11389
关键词
Neoadjuvant chemotherapy; borderline resectable; pancreatic cancer
类别
Background/Aim: The aim of this study was to investigate the safety and feasibility of neoadjuvant nabpaclitaxel plus gemcitabine therapy for patients with borderline resectable pancreatic carcinoma (BRPC). Patients and Methods: The study was a prospective single-center phase I trial for patients with BRPC. The primary endpoint was the toxicity, and secondary endpoints were the resection rate, the R0 resection rate and quality of life (QOL) regarding the peripheral sensory neuropathy (PSN). This trial was registered on the UMIN Clinical Trials Registry (UMIN000018382) and on ClinicalTrials.gov (NCT02506803). Results: The overall rate of any grade and grade 3-4 events (CTCAE ver. 4.0 criteria) were 100% and 90%. The majority of these adverse events represented expected neutropenia. The resection and R0 resection rates were 80% and 70%, respectively. Conclusion: We found that neoadjuvant nab-paclitaxel plus gemcitabine therapy was safe and feasible without stringent selection of patients with BRPC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据